There are 2137 resources available
714P - Time to deterioration in quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214
Presenter: David Cella
Session: E-Poster Display
Resources:
Abstract
715P - Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC)
Presenter: Bilal Siddiqui
Session: E-Poster Display
Resources:
Abstract
716P - Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study
Presenter: Frank Stenner-Liewen
Session: E-Poster Display
Resources:
Abstract
717P - Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk
Presenter: Toni Choueiri
Session: E-Poster Display
Resources:
Abstract
718P - A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
Presenter: Thomas Powles
Session: E-Poster Display
Resources:
Abstract
719P - Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
Presenter: Chung-Han Lee
Session: E-Poster Display
Resources:
Abstract
720P - Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study
Presenter: Antoine Thiery-Vuillemin
Session: E-Poster Display
Resources:
Abstract
721P - Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study
Presenter: Umberto Basso
Session: E-Poster Display
Resources:
Abstract
722P - Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study
Presenter: Marine Gross-Goupil
Session: E-Poster Display
Resources:
Abstract
723P - Response to systemic therapy in fumarate hydratase (FH) mutated papillary renal cell carcinoma (pRCC): Is there a winner?
Presenter: Lucia Carril
Session: E-Poster Display
Resources:
Abstract